Mechanisms for the transition from physiological to pathological cardiac hypertrophy.

adaptive cardiac hypertrophy cardiac contractile function cardiac hypertrophy cardiac remodeling fonction cardiaque contractile hypertrophie cardiaque hypertrophie cardiaque adaptative hypertrophie cardiaque pathologique hypertrophie cardiaque physiologique pathological cardiac hypertrophy physiological cardiac hypertrophy remodelage cardiaque

Journal

Canadian journal of physiology and pharmacology
ISSN: 1205-7541
Titre abrégé: Can J Physiol Pharmacol
Pays: Canada
ID NLM: 0372712

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 10 12 2019
medline: 18 11 2020
entrez: 10 12 2019
Statut: ppublish

Résumé

The heart is capable of responding to stressful situations by increasing muscle mass, which is broadly defined as cardiac hypertrophy. This phenomenon minimizes ventricular wall stress for the heart undergoing a greater than normal workload. At initial stages, cardiac hypertrophy is associated with normal or enhanced cardiac function and is considered to be adaptive or physiological; however, at later stages, if the stimulus is not removed, it is associated with contractile dysfunction and is termed as pathological cardiac hypertrophy. It is during physiological cardiac hypertrophy where the function of subcellular organelles, including the sarcolemma, sarcoplasmic reticulum, mitochondria, and myofibrils, may be upregulated, while pathological cardiac hypertrophy is associated with downregulation of these subcellular activities. The transition of physiological cardiac hypertrophy to pathological cardiac hypertrophy may be due to the reduction in blood supply to hypertrophied myocardium as a consequence of reduced capillary density. Oxidative stress, inflammatory processes, Ca

Identifiants

pubmed: 31815523
doi: 10.1139/cjpp-2019-0566
doi:

Substances chimiques

Cytokines 0
Calcium SY7Q814VUP

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-84

Auteurs

Christopher J Oldfield (CJ)

Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB R2H 2A6, Canada.

Todd A Duhamel (TA)

Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB R2H 2A6, Canada.

Naranjan S Dhalla (NS)

Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB R2H 2A6, Canada.
Department of Physiology & Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH